SG11201908771YA - Modified oligonucleotides and therapeutic uses thereof - Google Patents
Modified oligonucleotides and therapeutic uses thereofInfo
- Publication number
- SG11201908771YA SG11201908771YA SG11201908771YA SG11201908771YA SG 11201908771Y A SG11201908771Y A SG 11201908771YA SG 11201908771Y A SG11201908771Y A SG 11201908771YA SG 11201908771Y A SG11201908771Y A SG 11201908771YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- california
- road
- san diego
- torrey pines
- Prior art date
Links
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Chemical class Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title abstract 3
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 108091034117 Oligonucleotide Proteins 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 125000003729 nucleotide group Chemical group 0.000 abstract 2
- 230000035515 penetration Effects 0.000 abstract 2
- 102000009027 Albumins Human genes 0.000 abstract 1
- 108010088751 Albumins Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000005313 fatty acid group Chemical group 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762475185P | 2017-03-22 | 2017-03-22 | |
| PCT/US2018/023578 WO2018175592A1 (en) | 2017-03-22 | 2018-03-21 | Modified oligonucleotides and therapeutic uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201908771YA true SG11201908771YA (en) | 2019-10-30 |
Family
ID=63586170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201908771Y SG11201908771YA (en) | 2017-03-22 | 2018-03-21 | Modified oligonucleotides and therapeutic uses thereof |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20200046846A1 (enExample) |
| EP (1) | EP3600439A4 (enExample) |
| JP (1) | JP2020514383A (enExample) |
| KR (1) | KR20190123351A (enExample) |
| CN (1) | CN110636865A (enExample) |
| AU (1) | AU2018237139A1 (enExample) |
| CA (1) | CA3057292A1 (enExample) |
| SG (1) | SG11201908771YA (enExample) |
| WO (1) | WO2018175592A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250270248A1 (en) * | 2020-09-16 | 2025-08-28 | Astrazeneca Ab | Oligonucleotides conjugated to fatty acids |
| CN117980003A (zh) * | 2021-09-10 | 2024-05-03 | 嘉德治疗有限责任公司 | 核酸的脂肪酸缀合物 |
| WO2025028656A1 (ja) * | 2023-08-02 | 2025-02-06 | 日東電工株式会社 | オリゴヌクレオチドを製造する方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0821001A4 (en) * | 1995-03-31 | 2002-07-17 | Drug Delivery System Inst Ltd | AMIDITY DERIVATIVES AND OLIGONUCLEOTIDE DERIVATIVES |
| US8969543B2 (en) * | 2003-04-03 | 2015-03-03 | Bioneer Corporation | SiRNA-hydrophilic polymer conjugates for intracellular delivery of siRNA and method thereof |
| WO2007112414A2 (en) * | 2006-03-27 | 2007-10-04 | Isis Pharmaceuticals, Inc. | Conjugated double strand compositions for use in gene modulation |
| KR101224828B1 (ko) * | 2009-05-14 | 2013-01-22 | (주)바이오니아 | ｓｉＲＮＡ 접합체 및 그 제조방법 |
| GB0910723D0 (en) * | 2009-06-22 | 2009-08-05 | Sylentis Sau | Novel drugs for inhibition of gene expression |
| CN103649311A (zh) * | 2011-06-03 | 2014-03-19 | 国立大学法人北海道大学 | 寡核苷酸衍生物、包含寡核苷酸衍生物的治疗用医药组合物及诊断用医药组合物、以及miRNA机能抑制用寡核苷酸衍生物 |
| RU2599449C1 (ru) * | 2011-12-15 | 2016-10-10 | Байонир Корпорейшн | Новые конъюгаты олигонуклеотидов и их применение |
| DK3019200T3 (da) * | 2013-07-11 | 2022-06-20 | Alnylam Pharmaceuticals Inc | Oligonukleotid-ligand-konjugater og fremgangsmåde til fremstiling deraf |
| CN105792851B (zh) * | 2013-09-13 | 2023-10-10 | 斯克利普斯研究所 | 修饰的治疗剂及其组合物 |
| AU2014364589B2 (en) * | 2013-12-18 | 2020-02-27 | The California Institute For Biomedical Research | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof |
| JP6773677B2 (ja) * | 2015-03-17 | 2020-10-21 | アローヘッド ファーマシューティカルズ インコーポレイテッド | 改善されたジスルフィド含有アルキン連結剤 |
| MA41794A (fr) * | 2015-03-18 | 2018-01-23 | The California Institute For Biomedical Res | Agents thérapeutiques modifiés et compositions associées |
| WO2017030973A1 (en) * | 2015-08-14 | 2017-02-23 | University Of Massachusetts | Bioactive conjugates for oligonucleotide delivery |
| AU2016326392B2 (en) * | 2015-09-22 | 2021-02-11 | The Regents Of The University Of California | Modified cytotoxins and their therapeutic use |
-
2018
- 2018-03-21 AU AU2018237139A patent/AU2018237139A1/en not_active Abandoned
- 2018-03-21 JP JP2019551984A patent/JP2020514383A/ja active Pending
- 2018-03-21 EP EP18770600.7A patent/EP3600439A4/en not_active Withdrawn
- 2018-03-21 WO PCT/US2018/023578 patent/WO2018175592A1/en not_active Ceased
- 2018-03-21 CA CA3057292A patent/CA3057292A1/en not_active Abandoned
- 2018-03-21 KR KR1020197030864A patent/KR20190123351A/ko not_active Ceased
- 2018-03-21 US US16/492,642 patent/US20200046846A1/en not_active Abandoned
- 2018-03-21 SG SG11201908771Y patent/SG11201908771YA/en unknown
- 2018-03-21 CN CN201880026265.5A patent/CN110636865A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018237139A1 (en) | 2019-10-17 |
| EP3600439A1 (en) | 2020-02-05 |
| KR20190123351A (ko) | 2019-10-31 |
| CN110636865A (zh) | 2019-12-31 |
| JP2020514383A (ja) | 2020-05-21 |
| WO2018175592A1 (en) | 2018-09-27 |
| US20200046846A1 (en) | 2020-02-13 |
| EP3600439A4 (en) | 2021-01-13 |
| CA3057292A1 (en) | 2018-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201901364VA (en) | Engineered target specific nucleases | |
| SG11201811232XA (en) | Treatment of amd using aav2 variant with aflibercept | |
| SG11201805162VA (en) | Plasmid constructs for heterologous protein expression and methods of use | |
| SG11201901841TA (en) | Targeting ligands | |
| SG11201807187XA (en) | Binding members to pd-l1 | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201908131RA (en) | Benzazepine compounds, conjugates, and uses thereof | |
| SG11201908743SA (en) | Methods and compositions for modulation of immune cells | |
| SG11201808619QA (en) | Nucleic acid-polypeptide compositions and uses thereof | |
| SG11201804375WA (en) | Compositions and methods for internalizing enzymes | |
| SG11202000312UA (en) | Encapsulated polynucleotides and methods of use | |
| SG11201903737PA (en) | Neutralizing anti-tl1a monoclonal antibodies | |
| SG11201805320XA (en) | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration | |
| SG11201808920RA (en) | Genome editing of human neural stem cells using nucleases | |
| SG11201811290VA (en) | Compositions and methods for the depletion of cd117+cells | |
| SG11201808676RA (en) | Methods of treating pediatric cancers | |
| SG11201808762XA (en) | Diagnostic methods for patient specific therapeutic decision making in cancer care | |
| SG11201903155XA (en) | Pharmaceutical compounds | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201909513QA (en) | Prodrugs of 2-pmpa for healthy tissue protection during psma-targeted cancer imaging or radiotherapy | |
| SG11201811559WA (en) | Cancer treatment combinations | |
| SG11201908512YA (en) | Somatostatin modulators and uses thereof |